



Business Results for The First Three Quarters of FY2007

(Nine-month period ended December 31, 2007)

Miraca Holdings Inc.

1



Disclaimer regarding forward-looking statement:

The forward-looking statements contained in this document are based on various assumptions and beliefs in light of the information currently available to management, and involve significant risks or uncertainties. Please be aware that the actual performance may differ materially from these statements as a result of various contributing factors.

Factors affecting the performance include but not limited to: general industry and market conditions, economic conditions, fluctuation of exchange rate, change of regulatory, statutory and administrative requirements, competitive situation, delayed launch of new products/services, and decline of the sales potential of existing products/services.

2

FY2007/1-3Q Outline of Consolidated Financial Results

(billion yen)

	FY06/1-3Q Results	FY07/1-3Q		FY2007	
		Results	YoY Change	Forecast	9-month Achievement
Net Sales	104.9	107.2	2.3 2.2%	142.0	75.5%
In Vitro Diagnostics	23.5	23.8	0.3 1.3%	32.5	73.2%
Clinical Lab Testing	67.2	68.1	0.9 1.3%	89.4	76.2%
Others	14.2	15.2	1.0 7.0%	20.1	75.6%
Operating Profit	(*) 11.75 11.2%	(*) 11.97 11.2%	0.22 1.9%	15.50 10.9%	77.2%
In Vitro Diagnostics	6.12 26.0%	5.36 22.5%	-0.76 -12.4%	6.90 21.2%	77.7%
Clinical Lab Testing	4.04 6.0%	4.89 7.2%	0.85 21.0%	6.60 7.4%	74.1%
Others	1.52 10.7%	1.74 11.4%	0.22 14.5%	2.10 10.4%	82.9%
Ordinary Profit	12.10 11.5%	12.44 11.6%	0.34 2.8%	15.70 11.1%	79.2%
Net Income	7.02 6.7%	(**) 6.68 6.2%	-0.34 -4.8%	8.80 6.2%	75.9%

(*) Operating profit of 11.75 billion yen for FY2006/1-3Q includes elimination/corporate of 0.07 billion yen.
Operating profit of 11.97 billion yen for FY2007/1-3Q includes elimination/corporate of -0.03 billion yen.

(**) Net extraordinary loss for FY2007/1-3Q is 1.09 billion yen, which includes restructuring expenses such as premium severance pay for early retirement at SRL Kansai (0.69 billion yen).

Net extraordinary loss for FY2006/1-3Q is 0.4 billion yen.

※ Forecast of FY2007 is based on the figures in the presentation "FY2007 The First Half-year Results" (Nov.14, 2007).


※ In principal, figures of net sales are rounded to the nearest 100 million yen. Figures of operating profit, ordinary profit, and net income are rounded to the nearest 10 million yen.

3

FY2007/1-3Q Segment Overview 1. In vitro Diagnostics Business

(billion yen)

Net Sales



Sales Up, Profit Down (year-on-year)

◆ Net sales: +0.3 bn yen

- Expansion of anti-body supply at the overseas subsidiary
- Introduction of CL4800^(*) instruments at Japanese Red Cross

◆ Operating profit: -0.76 bn yen


- Increase in cost of goods sold caused by product mix change: 0.3 bn yen
(The sales volume of testing instruments was higher in Q3.)

- Profit decline attributed to increase of R&D expenses (testing-instruments-related): 0.3 bn yen
(R&D spending increased in Q3.)

The increased portion of R&D budget for FY07 has been implemented.

(billion yen)

Operating Profit




* Figures of net sales are rounded to the nearest 100 million yen. (*) CL4800: the newly launched testing system for blood screening
* Figures of operating profit are rounded to the nearest 10 million yen.

4


FY2007/1-3Q Segment Overview

2. Clinical Lab Testing Business



Increase in Sales and Profit (year-on-year)

- ◆ **Net sales: +0.9 bn yen**
 - **Off-site testing:** Remained the same level (+0.1 bn yen)
 - **FMS^(*)/Branch-lab:** Stable growth (+0.8 bn yen)



- ◆ **Operating profit: +0.85 bn yen**
 - Increase of marginal profit from sales growth
 - Reduction in personnel and general expenses


Downturn in profitability was mainly attributed to the expenses for the construction/relocation of SRL Kansai Lab and temporary increased personnel expenses for personnel-system reform.

* Figures of net sales are rounded to the nearest 100 million yen.
 * Figures of operating profit are rounded to the nearest 10 million yen.


(*) FMS: Facility Management Service

FY2007/1-3Q Segment Overview

3. Other Businesses



Stable Increase in Clinical Trials and Sterilizing (year-on-year)



YOY change	◆ Sales Change (yen)	◆ Op Profit Change (yen)	
Clinical Trials	+0.7 bn	+0.25 bn	• Continuing growth in both Clinical trial testing and CRO ^(*) business
Sterilizing	+0.8 bn	+0.16 bn	• The accumulated number of accounts is increasing
Preventive Medicine Related	-0.4 bn	-0.19 bn	• Stagnant sales of health promotion products

* Figures of net sales are rounded to the nearest 100 million yen.
 * Figures of operating profit are rounded to the nearest 10 million yen.

(*) CRO: Contract Research Organization

Further contact:

Miraca Holdings Inc.

Phone: +81-3-5909-3337

Akira Uchida ar-uchida@miraca-holdings.co.jp
Manager, IR Public Relations Group

Kazumi Yokokawa km-yokokawa@miraca-holdings.co.jp
IR Public Relations Group

Harumi Tanaka hm-tanaka@miraca-holdings.co.jp
IR Public Relations Group